TriVerity gets FDA breakthrough device designation

December 2023—Inflammatix announced that the FDA has granted breakthrough device designation to its TriVerity acute infection and sepsis test system. The system, which is currently under development, includes the TriVerity test and Myrna instrument.

TriVerity provides three readouts to facilitate diagnosis and prognosis of adult patients with suspected acute infection or sepsis who present in an emergency department. The Myrna instrument is capable of sample-to-answer quantitation of up to 64 mRNAs from whole blood or other sample types in about 30 minutes.

Inflammatix, 650-443-3030